Retatrutide and Cagrilintide act on two entirely separate receptor families, incretin and glucagon receptors versus the amylin receptor, which is exactly why they are studied together rather than treated as interchangeable metabolic-research compounds.
HPLC certified
Independent analysis
Highest standard
Full traceability
The Incretin + Amylin kit pairs Retatrutide 10mg with Cagrilintide 5mg, two metabolic-research peptides that act on entirely separate receptor systems rather than overlapping mechanisms.
Retatrutide is studied as a triple agonist across GIP, GLP-1, and glucagon receptors. Cagrilintide is studied as a long-acting amylin receptor agonist, a separate appetite-regulation pathway from the incretin system Retatrutide operates in.
Both vials ship individually labeled and independently HPLC-verified before batch release. This product is intended strictly for laboratory research use only and is not approved for human consumption.
The Incretin + Amylin kit pairs Retatrutide 10mg with Cagrilintide 5mg, two metabolic-research peptides that act on entirely separate receptor systems rather than overlapping mechanisms. Retatrutide is a triple agonist working across GIP, GLP-1, and glucagon receptors, while Cagrilintide works through the amylin receptor, a completely separate signaling system. Researchers studying energy-expenditure and appetite-regulation pathways together, rather than a single receptor family in isolation, are the primary audience for this pairing.
Metabolic-research peptides tend to fall into a small number of receptor families, and Retatrutide and Cagrilintide were chosen for this kit because they come from two different ones. This distinction matters in study design: pairing two incretin-pathway peptides would largely duplicate the same receptor system, while pairing an incretin/glucagon agonist with an amylin agonist lets a single protocol examine two independently regulated appetite and energy-expenditure pathways at once.
| Vial | Peptide | Strength | Research Focus |
|---|---|---|---|
| Vial 1 | Retatrutide | 10mg | Triple GIP/GLP-1/glucagon receptor agonism in metabolic and energy-expenditure research. |
| Vial 2 | Cagrilintide | 5mg | Long-acting amylin receptor agonism in appetite-regulation research. |
Retatrutide is studied as a triple receptor agonist targeting GIP, GLP-1, and glucagon receptors simultaneously, distinguishing it from single- or dual-agonist compounds in metabolic and energy-expenditure research. Because it engages three receptor systems at once, Retatrutide research often serves as a broader reference point against which single-target incretin compounds are compared.
Cagrilintide is a long-acting amylin receptor agonist. Amylin signaling is studied as a separate appetite-regulation pathway from the incretin system Retatrutide operates in, which is the specific reason the two are paired here rather than, for example, bundling Retatrutide with another incretin-pathway compound. Amylin and incretin signaling are frequently studied together specifically because their combined effect on appetite regulation is a distinct research question from either pathway studied in isolation. Cagrilintide's long-acting profile is also itself a research variable, since duration of receptor engagement is frequently compared against shorter-acting amylin analogs in pharmacokinetic-focused study designs.
Researchers new to metabolic peptide research sometimes default to stacking multiple compounds from the same receptor family, assuming more incretin-pathway agonists will yield a more complete picture. In practice, the more informative research design usually involves sampling from genuinely separate systems, which is the logic behind this kit's structure. Retatrutide's three-receptor profile already provides broad incretin and glucagon coverage on its own, so the more useful second compound is one that operates through an unrelated pathway entirely, which is exactly the role Cagrilintide's amylin-receptor activity plays here.
For a broader metabolic panel that adds lipid-metabolism and mitochondrial research angles, see Metabolic Support, which also includes Retatrutide alongside AOD-9604 and MOTS-c. For mitochondrial-biogenesis-focused metabolic research instead, see Metabolic Activation. Browse the full Peptide Bundles collection for the complete lineup.
Both vials ship individually labeled with compound name, strength, and batch lot number and are not co-formulated. Each is independently HPLC-verified for identity and purity before batch release, with Certificates of Analysis available per component batch on request, the same documentation provided when either peptide is purchased on its own.
This product is intended strictly for laboratory research use only. It is not approved for human consumption, therapeutic application, or diagnostic purposes.
Telomerase enzyme explained: how TERT and TERC maintain telomeres, why it matters in aging and cancer research, plus RUO peptide sourcing. Read the guide.
KLOW peptide research blend is drawing attention across California's research community. Discover its composition, COA basics, and current evidence limits.
Learn what a peptide bond is, how it forms through dehydration synthesis, and why its structure matters for research peptides. Read the full guide now.
(faqs)
